BMO Capital Markets Raises Replimune Group (NASDAQ:REPL) Price Target to $18.00

Replimune Group (NASDAQ:REPL) had its price target upped by equities researchers at BMO Capital Markets from $14.00 to $18.00 in a research note issued on Friday,Benzinga reports. The brokerage presently has an “outperform” rating on the stock. BMO Capital Markets’ price objective indicates a potential upside of 12.99% from the stock’s previous close.

Several other research firms have also recently commented on REPL. Roth Capital raised shares of Replimune Group to a “strong-buy” rating in a research note on Tuesday, August 27th. HC Wainwright reiterated a “buy” rating and issued a $17.00 target price on shares of Replimune Group in a research note on Friday. JPMorgan Chase & Co. raised their price target on Replimune Group from $14.00 to $17.00 and gave the stock an “overweight” rating in a research note on Tuesday, September 24th. Finally, Roth Mkm initiated coverage on Replimune Group in a report on Tuesday, August 27th. They issued a “buy” rating and a $17.00 price target for the company. Six investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, the stock has an average rating of “Buy” and a consensus target price of $17.00.

Replimune Group Price Performance

Shares of REPL traded up $4.88 on Friday, reaching $15.93. The stock had a trading volume of 3,216,762 shares, compared to its average volume of 1,041,668. The firm has a 50-day moving average of $11.51 and a 200 day moving average of $9.67. The firm has a market capitalization of $1.09 billion, a PE ratio of -5.22 and a beta of 1.19. Replimune Group has a twelve month low of $4.92 and a twelve month high of $17.00. The company has a quick ratio of 10.11, a current ratio of 10.11 and a debt-to-equity ratio of 0.18.

Replimune Group (NASDAQ:REPL) last posted its earnings results on Tuesday, November 12th. The company reported ($0.68) earnings per share for the quarter, beating the consensus estimate of ($0.75) by $0.07. Sell-side analysts expect that Replimune Group will post -3.02 EPS for the current year.

Insider Buying and Selling at Replimune Group

In related news, insider Konstantinos Xynos sold 7,246 shares of the business’s stock in a transaction dated Monday, November 18th. The stock was sold at an average price of $10.78, for a total value of $78,111.88. Following the completion of the sale, the insider now directly owns 109,885 shares of the company’s stock, valued at $1,184,560.30. The trade was a 6.19 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. 8.80% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Replimune Group

Large investors have recently added to or reduced their stakes in the stock. Nisa Investment Advisors LLC increased its holdings in shares of Replimune Group by 10,304.2% during the second quarter. Nisa Investment Advisors LLC now owns 4,994 shares of the company’s stock valued at $45,000 after purchasing an additional 4,946 shares during the period. Point72 DIFC Ltd acquired a new position in Replimune Group during the 2nd quarter valued at about $57,000. Erste Asset Management GmbH bought a new stake in shares of Replimune Group during the 3rd quarter worth about $133,000. Arizona State Retirement System acquired a new stake in shares of Replimune Group in the 2nd quarter worth approximately $108,000. Finally, China Universal Asset Management Co. Ltd. lifted its stake in shares of Replimune Group by 82.1% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 13,140 shares of the company’s stock worth $144,000 after acquiring an additional 5,926 shares during the period. 92.53% of the stock is owned by institutional investors and hedge funds.

About Replimune Group

Replimune Group, Inc, a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma.